Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Haluska

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Molecular Cancer Therapeutics|February 20, 2015
A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgraftsMarc A Becker, Paul Haluska, Laurie K Bale, et al.
Endocrine-Related Cancer|October 10, 2012
Hormone response in ovarian cancer: time to reconsider as a clinical target?Francesmary Modugno, Robin Laskey, Ashlee L Smith, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|May 4, 2012
Quantifying insulin receptor isoform expression in FFPE breast tumorsSean C Harrington, S John Weroha, Carol Reynolds, et al.
Plos One|May 12, 2015
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraftGretchen Glaser, S John Weroha, Marc A Becker, et al.
Frontiers in Bioscience (Elite Edition)|June 2, 2012
An organ system based approach to prognosis in advanced melanomaShernan G Holtan, Aaron S Mansfield, Douglas J Creedon, et al.
BMC Cancer|October 22, 2016
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancerMarc A Becker, Xiaonan Hou, Piyawan Tienchaianada, et al.
Cancer Research|September 16, 2010
Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathwayCatherine J Huntoon, Monica D Nye, Liyi Geng, et al.
Endocrine-Related Cancer|April 14, 2010
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumorsJudith A Gilbert, Laura J Adhikari, Ricardo V Lloyd, et al.
Investigational New Drugs|January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsJoleen Hubbard, Charles Erlichman, David O Toft, et al.
Molecular Cancer Therapeutics|September 4, 2008
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924Paul Haluska, Joan M Carboni, Cynthia TenEyck, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Molecular Cancer Therapeutics|February 20, 2015
A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgraftsMarc A Becker, Paul Haluska, Laurie K Bale, et al.
Endocrine-Related Cancer|October 10, 2012
Hormone response in ovarian cancer: time to reconsider as a clinical target?Francesmary Modugno, Robin Laskey, Ashlee L Smith, et al.
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society|May 4, 2012
Quantifying insulin receptor isoform expression in FFPE breast tumorsSean C Harrington, S John Weroha, Carol Reynolds, et al.
Plos One|May 12, 2015
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraftGretchen Glaser, S John Weroha, Marc A Becker, et al.
Frontiers in Bioscience (Elite Edition)|June 2, 2012
An organ system based approach to prognosis in advanced melanomaShernan G Holtan, Aaron S Mansfield, Douglas J Creedon, et al.
BMC Cancer|October 22, 2016
Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancerMarc A Becker, Xiaonan Hou, Piyawan Tienchaianada, et al.
Cancer Research|September 16, 2010
Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathwayCatherine J Huntoon, Monica D Nye, Liyi Geng, et al.
Endocrine-Related Cancer|April 14, 2010
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumorsJudith A Gilbert, Laura J Adhikari, Ricardo V Lloyd, et al.
Investigational New Drugs|January 19, 2010
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumorsJoleen Hubbard, Charles Erlichman, David O Toft, et al.
Molecular Cancer Therapeutics|September 4, 2008
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924Paul Haluska, Joan M Carboni, Cynthia TenEyck, et al.
Pageof 7